History of Parkinson's disease

Handbook of Clinical Neurology

Volumn 83, Issue , 2007, Pages

  Goldman, Jennifer G ^a   Goetz, Christopher G ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649303339     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)83005-3     Document Type: Review

References (105)

1. Bechet E. Formes cliniques et diagnostic de la maladie de Parkinson (1892) 135 Thesis, Paris (case XIX,)
2. Bertler A., and Rosengren E. Occurrence and distribution of dopamine in brain and other tissues. Experientia 15 (1959) 10-11
3. Birkmayer W., and Hornykiewicz O. Der l-3,4-dioxyphenylalanin (=DOPA)-Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 73 (1961) 787-788
4. Blaschko H. The specific action of L-dopa decarboxylase. J Physiol 95 (1939) 50
5. Blocq P., and Marinesco G. Sur un cas de tremblement parkinsonien hemiplegique symptomatique du à une tumeur du pedoncle cerebral. Rev Neurol 2 (1894) 265
6. Braak H., Ghebremedhin E., Rub U., et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318 (2004) 121-134
7. Burn J.H., and Rand M.J. The effect of precursors of noradrenaline on the response to tyramine and sympathetic stimulation. Br J Pharm 15 (1960) 47-55
8. Calne D.B., Teychenne P.F., Claveria L.E., et al. Bromocriptine in parkinsonism. Br Med J 4 (1974) 442-444
9. Barbeau A., Murphy G.F., and Sourkes T.L. Les catécholamines dans la maladie de Parkinson. In: Ajuriaguerra J. (Ed). Monoamines et Système Nerveux Central (1962), Georg, Geneva 247-262
10. Cane D.B., Dubbing A., and Stern G. Did Leonardo describe Parkinson's disease?. N Engle J Med 320 (1989) 594
11. Carlson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 11 (1959) 490-493
12. Carlson A. A half-century of neurotransmitter research: impact on neurology and psychiatry. From Nobel Prize lecture. Available online at: (2000). http://Nobelprize.org/medicine/laureates
13. Carlson A., Lindqvist M., and Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nat Lond 180 (1957) 1200
14. Carlson A., Lindqvist M., Magnusson T., et al. On the presence of 3-hydroxytyramine in brain. Science 127 (1958) 471
15. Charcot J.M. Leçons du mardi á la Salpêtrière 1887-1888. Bureaux du Progrès Medical, Paris, leçons 9 (1887) 22
16. Cooper I.S. Ligation of the anterior choroidal artery for involuntary movements of parkinsonism. Arch Neurol 75 (1956) 36
17. Cotzias G.C., Van Woert M.H., and Schiffer L.M. Aromatic amino acids and modification of parkinsonism. N Engle J Med 276 (1967) 374-379
18. Cotzias G.C., Papvasiliou P.S., and Gellene R. Modification of parkinsonism-chronic treatment with l-dopa. N Engle J Med 280 (1969) 337-345
19. Currier R.D. Did John Hunter give James Parkinson an idea?. Arch Neurol 53 (1996) 377-378
20. Davis G.C., Williams A.C., Markey S.P., et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatr Res 1 (1979) 249-254
21. Degkwitz R., Frowein R., Kulenkampff C., et al. Über die Wirkungen des l-DOPA beim Menschen und deren Beein flussung durch Reserpin, Chlorpromazin, Iproniazid und Vitamin B6. Klin Wochenschr 38 (1960) 120-123
22. Denny-Brown D. Diseases of the basal ganglia: their relation to disorders of movement. Lancet 2 (1960) 1099-1105
23. Denny-Brown D. Diseases of the basal ganglia: their relation to disorders of movement. Lancet 2 (1960) 1155-1162
24. Dewey R.B., Hutton J.T., LeWitt P., et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 58 (2001) 1385-1392
25. Dickman M.S. Von Economo encephalitis. Arch Neurol 58 (2001) 1696-1698
26. Dole V.P. George Constantin Cotzias, pp (2006) 63-83. http://www.nap.edu/readingroom/books/biomems Available online at:
27. Duvoisin R.C. A brief history of parkinsonism. Neurol Clin 10 (1992) 301-316
28. Duvoisin R.C., and Yahr M.D. Encephalitis and parkinsonism. Arch Neurol 12 (1965) 227-239
29. Ehringer H., and Hornykiewicz O. Verteilung von noradrenalin und dopamin (3-hydoxytyramin) im gehirn des menschen und ihr verhalten bei erkankungen des extrapyramidalen systems. Klin Wochenschr 38 (1960) 1236-1239
30. Ehringer H., and Hornykiewicz O. Verteilung von noradrenalin und dopamin (3-hydoxytyramin) im gehirn des menschen und ihr verhalten bei erkankungen des extrapyramidalen systems. English translation: Parkinsonism Rel Dis 4 (1998) 53-57
31. Elliotson J. St. Thomas's Hospital. Clinical lecture. Lancet 1 (1830) 119-124
32. Elmer L. Paralysis agitans-refining the diagnosis and treatment. In: Ebadi M., and Pfeiffer R.F. (Eds). Parkinson's Disease (2005), CRC Press, Boca Raton 21-26
33. Fahn S., Oakes D., Shoulson I., et al. Levodopa and the progression of Parkinson's disease. N Engle J Med 351 (2004) 2498-2508
34. Fall P.A., Fredrikson M., Axelson O., et al. Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. Move Disord 14 (1999) 28-37
35. Foix C., and Nicolesco J. Les Noyaux gris centraux et la Région Mesencephalo-sours-Optique (1925), Masson, Paris
36. Freedman B.J. Preparkinsonian parkinsonism. Br Med J 298 (1989) 1573
37. Goetz C.G. Charcot on Parkinson's disease. Mov Disord 1 (1986) 27-32
38. Goetz C.G. Charcot and Parkinson's disease. In: Factor S.A., and Weiner W.J. (Eds). Parkinson's Disease: Diagnosis and Clinical Management (2002), Demos, New York 19-26
39. Goetz C.G., Chmura T.A., and Lanska D.J. Seminal figures in the history of movement disorders: Gilles de la Tourette, Oppenheim, the Vogts, von Economo, Wilson and Marsen. Part 12 of the MDS-sponsored History of Movement Disorders exhibit, Barcelona, June 2000. Mov Disord 16 (2001) 940-946
40. Golbe L.I., Di Iorio G., Bonavita V., et al. A large kindred with autosomal dominant Parkinson's disease. Ann Neurol 27 (1990) 276-282
41. Goodall M. Studies of adrenaline and noradrenaline in mammalian heart and suprarenals. Acta Physiol Scand Suppl 24 (1951) 7-51
42. Greenfield J.G., and Bosanquet F. The brain stem lesions in parkinsonism. J Neurol Neurosurg Psychiatry 16 (1953) 213-226
43. Haas L.F. Cecile Vogt (1875-1962). J Neurol Neurosurg Psychiatry 73 (2002) 315
44. Hall M. Lectures on the theory and practice of medicine. Lancet 2 (1838) 41
45. Hallervorden J. Anatomische Untersuchungen Zur Pathogenese des postenzephalitischer Parkinsonismus. Deutsche Zeitscr Nervenhielk 136 (1935) 68-77
46. Hassler R. Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J Psychol Neurol 48 (1938) 387
47. Hassler R. The pathological and pathophysiological basis of tremor and parkinsonism. Second International Congress of Neuropathology (1955), Excerpta Medical Foundation, Amsterdam 2940
48. Herzberg L. An essay on the shaking palsy: reviews and notes on the journals in which they appeared. Mov Disord 5 (1990) 162-166
49. Hoehn M.M., and Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 17 (1967) 427-442
50. Hornykiewicz O. Dopamine and Parkinson's disease: a person view of the past, the present and the future. Adv Neurol 86 (2001) 1-11
51. Holtz P. Dopadecarboxylase. Natur wissen schaften 27 (1939) 724-725
52. Hornykiewicz O. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent. Amino Acids 23 (2002) 65-70
53. Hornykiewicz O. Dopamine miracle: from brain homogenate to dopamine replacement. Mov Disord 17 (2002) 501-508
54. Kapp W. The history of drugs for the treatment of Parkinson's disease. J Neural Transm 38 Suppl (1992) 1-6
55. Klaue R. Parkinson Krankheit (Paralysis Agitans) und postencephalitischer Parkinsonismus. Arch Psychiat Nervenkrank 111 (1940) 251-321
56. Koehler P.J., and Keyser A. Tremor in latin texts of dutch physicians: 16th-18th centuries. Mov Disord 12 (1997) 798-806
57. Lakke J.P.W.F. Images of Parkinson's disease, past and present. J Hist Neurosci 3 (1994) 131-138
58. Langston J.W., Ballard P., Tetrud J.W., et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
59. Langston J.W., Langston E.B., and Irwin I. MPTP-induced parkinsonism in human and non-human primates-clinical and experimental aspects. Acta Neurol Scand 70 Suppl 100 (1984) 49-54
60. Leroy E., Boyer R., Auburger G., et al. The ubiquitin pathway in Parkinson's disease. Nature 395 (1998) 451-452
61. Liou H.H., Tsai M.C., Chen C.J., et al. Environmental risk factors and Parkinosn's disease: a case-control study in Taiwan. Neurology 48 (1997) 1583-1588
62. Louis E.D. The shaking palsy, the first forty-five years: a journey through the british literature. Mov Disord 12 (1997) 1068-1072
63. Lucking C.B., Durr A., Bonifati V., et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engle J Med 342 (2000) 1560-1567
64. Manyam B.V., and Sanchez-Ramos J.R. Traditional and complementary therapies in Parkinson's disease. Adv Neurol 80 (1999) 565-574
65. Marder K., Tang M.X., Mejiz H., et al. Risk of Parkinson's disease among first-degree relatives: a community based study. Neurology 47 (1996) 155-160
66. Matsumine H., Saito M., Shimoda-Matsubayashi S., et al. Localization of a gene for an autosomal recessive form of juvenile parkinsonism to chromosome 6q25.2-27. Am J Hum Genet 60 (1997) 588-596
67. McNaught K.S.P., and Olanow C.W. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann Neurol 53 Suppl 3 (2003) S73-S86
68. Meyers R. Surgical procedure for postencephalitic tremor, with notes on the physiology of the premotor fibres. Arch Neurol Psychiatry 44 (1940) 455-459
69. Montagu K.A. Catechol compounds in rat tissues and in brains of different animals. Nature 180 (1957) 244-245
70. Morris A.D., and Rose F.C. James Parkinson: his life and times (1989), Birkhauser, Boston
71. Murrin L.C. The role of dopamine in Parkinson's disease: a historical review. In: Ebadi M., and Pfeiffer R.F. (Eds). Parkinson's Disease (2005), CRC Press, Boca Raton 21-26
72. Nagashayana N., Sankarankutty P., Nampoothiri M.R., et al. Association of L-DOPA with recovery following Ayurveda medication in Parkinson's disease. J Neurol Sci 176 (2000) 124-127
73. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., et al. The basal ganglia and disorders of movement: pathophysiological mechanisms. News Physiol Sci 17 (2002) 51-55
74. Ordenstein L. Sur la paralysie agitante et la sclérose en plaques généralisées (1867) Thesis, Paris
75. Papadimitriou A., Veletza V., Hadjigeorgiou G.M., et al. Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance. Neurology 52 (1999) 651-654
76. Parkinson J. Medical Admonitions to Families, Respecting the Preservation of Health and the Treatment of the Sick. 4th ed (1801), HD Symonds, London
77. Parkinson J. An Essay on the Shaking Palsy (1817), Sherwood, Neely & Jones, London
78. Parkinson Study Group. DATATOP: a multi-center controlled clinical trial in early Parkinson's disease. Arch Neurol 46 (1989) 1052-1060
79. Parkinson Study Group. An alternative medicine treatment for Parkinson's disease: results of a multicenter clinical trial. HP-200 in Parkinson's Disease Study Group. J Altern Complement Med 1 (1995) 249-255
80. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease. JAMA 284 (2000) 1931-1938
81. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61 (2004) 561-566
82. Patten B.M. A personal tribute to Dr. George C. Cotzias, clinician and scientist. Perspect Biol Med 27 (1983) 156-161
83. Pearce J.M.S. Aspects of the history of Parkinson's disease. J Neurol Neurosurg Psychiatry Suppl (1989) 6-10
84. Pearce J.M.S. The Lewy body. J Neurol Neurosurg Psychiatry 71 (2001) 214-215
85. Polymeropoulos M.H., Higgins J.J., Golbe L.I., et al. A gene for Parkinson's disease maps to 4q21-23. Science 274 (1996) 1197-1199
86. Polymeropoulos M.H., Lavedan C., Leroy E., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
87. Raab W., and Gigee W. Concentration and distribution of 'encephalin' in the brain of humans and animals. Proc Soc Exp Biol Med 76 (1951) 97-100
88. Rinne U.K., Sonninen V., and Siirtola T. Treatment of parkinsonian patients with levodopa and extracerebral decarboxylase inhibitor, Ro 4-4602. Adv Neurol 3 (1973) 59-71
89. Rocca W.A., McDonnell S.K., Strain K.J., et al. Familial aggregation of Parkinson's disease: the Mayo Clinic family study. Ann Neurol 56 (2004) 495-502
90. Ross G.W., Abbott R.D., Petrovitch H., et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283 (2000) 2674-2679
91. Sabbatini R. Neurons and synapses: the history of its discovery. Brain Mind 17 (2003)
92. Sano I., Gamo T., Kakimoto Y., et al. Distribution of catechol compounds in human brain. Biochim Biophys Acta 32 (1959) 586-587
93. Schiller F. Fritz Lewy and his bodies. J Hist Neurosci 9 (2000) 148-151
94. Schwab R.S., Amador L.V., and Levine J.Y. Apomorphine in Parkinson's disease. Trans Am Neurol Assoc 76 (1951) 273-279
95. Shults C.W., Oakes D., Kieburtz K., et al. Effects of coenzyme Q10 in early Parkinson's disease: evidence of slowing of the functional decline. Arch Neurol 59 (2002) 1541-1550
96. Smarigiassi A., Mutti A., DeRosa A., et al. A case-control study of occupational and environmental risk factors for Parkinson's disease in the Emilia-Romagna region of Italy. Neurotoxicology 19 (4-5) (1998) 709-712
97. Spiegel E.E., and Leksell L. A stereotaxic apparatus for intracerebral surgery. Acta Chir Scand 99 (1949) 229-233
98. Spillantini M.G., Schmidt M.L., Lee V.M., et al. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
99. Stern G. Did parkinsonism occur before 1817?. J Neurol Neurosurg Psychiatry Suppl (1989) 11-12
100. Tanner C.M., Ottman R., Goldman S., et al. Parkinson disease in twins: an etiologic study. JAMA 281 (1999) 341-346
101. Trietiakoff C. Contribution à l'étude de l'anatomie du locus niger de Soemmering (1919) Thesis, Paris
102. Vogt O., and Vogt C. Zur Lehre der Erkrankungen des striaren Systeme. J Psychol Neurol (1920) Lpz
103. Whone A.L., Watts R.L., Stoessel A.J., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54 (2003) 93-101
104. Yahr M.D., Duvoisin R.C., Schear M.J., et al. Treatment of parkinsonism with levodopa. Arch Neurol 21 (1969) 343-354
105. Zhang Z.X., Dong Z.H., and Schear G.C. Early descriptions of Parkinson's disease in ancient China. Arch Neurol 63 5 (2006) 782-784